Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Assets: 2013-2024

Historic Non-Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $344.6 million.

  • Amphastar Pharmaceuticals' Non-Current Assets rose 7.94% to $353.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.5 million, marking a year-over-year increase of 7.94%. This contributed to the annual value of $344.6 million for FY2024, which is 9.18% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Non-Current Assets stood at $344.6 million for FY2024, which was up 9.18% from $315.6 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Non-Current Assets' 5-year high stood at $344.6 million during FY2024, with a 5-year trough of $264.6 million in FY2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Non-Current Assets averaged around $308.3 million, with its median value being $315.6 million (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Non-Current Assets declined by 3.28% in 2021 and then increased by 19.30% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Non-Current Assets (Yearly) stood at $280.7 million in 2020, then declined by 3.28% to $271.5 million in 2021, then dropped by 2.55% to $264.6 million in 2022, then grew by 19.30% to $315.6 million in 2023, then rose by 9.18% to $344.6 million in 2024.